ArticleMedicine2026
The causal effect of cytokine cycling levels on the risk of cervical cancer: A bidirectional 2-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests that inflammatory protein factors are closely associated with the underlying mechanisms of cervical cancer. Therefore, 2-sample Mendelian randomization (MR) analysis was performed to assess the potential correlation between circulating inflammatory protein levels and cervical cancer risk. A 2-sample MR study, using genetic variants related to inflammatory proteins as instrumental variables, was conducted to improve the accuracy of cervical cancer diagnosis. By analyzing 14,824 individuals, 91 plasma proteins having strong association with single nucleotide polymorphisms were chosen as instrumental variables, with cervical cancer (909 cases and 238,249 controls) serving as outcome variables. The analysis of causal effects was completed using random effect inverse variance weighted, weighted median/mode, and MR-Egger. Sensitivity analysis was performed using Cochran Q test, funnel plots, leave-one-out analyses, MR-Egger intercept tests, as well as reverse MR analysis. Our analysis showed that C-C motif chemokine ligand 19 (CCL19), monocyte chemotactic protein-3 (MCP-3), and interleukin-12 (IL-12) was related to the risk of cervical cancer. Additionally, the inverse variance weighted method indicated that both CCL19 (OR: 1.479, 95% CI: 1.207-1.813, P = .0002) and IL-12 (OR: 1.171, 95% CI: 1.019-1.345, P = .0253) significantly increased the risk of cervical cancer. Nevertheless, MCP-3 levels may protect individuals from developing cervical cancer (OR, 0.647; 95% CI: 0.442-0.947, P = .0253). Furthermore, consistent outcomes were achieved in the sensitivity analysis. In our study, MR analysis of 91 inflammatory proteins revealed potential causal associations between CCL19, MCP-3, IL-12, and the etiology of cervical cancer. We believe that related inflammatory proteins will provide potential treatment opportunities for clinical interventions in cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.